Peer Review History
Original SubmissionJune 5, 2019 |
---|
PONE-D-19-15918 Investigation of the molecular biology underlying the pronounced high gene targeting frequency at Myh9 gene locus in mouse embryonic stem cells PLOS ONE Dear Dr Wang, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. We would appreciate receiving your revised manuscript by Oct 13 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Wenhui Hu, M.D., Ph.D. Academic Editor PLOS ONE Journal Requirements: 1. When submitting your revision, we need you to address these additional requirements. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability. Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized. Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access. We will update your Data Availability statement to reflect the information you provide in your cover letter. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: No Reviewer #2: Partly Reviewer #3: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: No Reviewer #2: N/A Reviewer #3: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: No Reviewer #3: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: No ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: In the manuscript entitled “Investigation of the molecular biology underlying the pronounced high gene targeting frequency at Myh9 gene locus in mouse embryonic stem cells”, the authors perform homologous recombination (HR) in mouse embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and embryonic fibroblasts (MEFs) to investigate the molecular features of the Myh9 gene locus that are responsible for the notably high efficiency of gene targeting. They perform comparative genetic sequence analysis of the Myh9 gene locus to illustrate a low degree of sequence conservation, which in turn suggests there are no unique genetic properties at these loci that affect recombination efficiency. By targeting their vector into the exon 2 region of Myh9 in mouse ESCs, iPSCs, and MEFs, the authors demonstrate a variable HR efficiency that is cell type-dependent but transcriptionally and translationally independent. The efficiency of HR also declines as the targeting vector is shifted downstream of exon 2, highlighting the contributions of local regions to recombination efficiency. Finally, the authors investigate the effects of modifying the lengths of the homology arms and discover an optimal ratio of 5’ to 3’ arm lengths for effective HR. Because gene editing has proven itself as an indispensable tool in biomedical research, primarily in enabling the generation of genetic models of development and disease, it is a worthwhile effort to understand the mechanisms regulating these processes. Despite the enormous strides in gene editing technology over the past decade using programmable nucleases, challenges remain in the field such as increasing the size of the targeting vector or minimizing off target genetic modifications. Understanding the properties of cis and trans factors affecting the efficiency of gene targeting through classical HR can yield mechanistic insights that have positive implications for other gene targeting technologies. While to goal of this manuscript is to advance the mechanistic understanding of how properties of the Myh9 locus enable such high gene targeting efficiencies through HR, the low experimental robustness and interpretation presented in this manuscript limit the validity of the conclusions drawn. It is by these qualities that this manuscript as submitted is not appropriate for publication in PLOS One, and descriptions of these qualities are outlined below. First, it is unclear in the written text what the authors aim to convey from the sequence comparisons across different species. Is there prior evidence that sequence conservation predicts strong recombination effects? Is there evidence that HR is high or low in ESCs of other species? If, for instance, HR efficiency is comparable in both rat and mouse ESCs (PMID: 20703227, PMID: 21151976), can conserved sequences be found across both loci? If there are discrepancies in HR efficiency across two species despite conserved sequences within syntenic elements, this could suggest differential epigenetic effectors. The authors can incorporate efficiency data from other ESC studies and better frame the interpretations drawn from their analysis. Furthermore, the data presented in Table 1, specifically the percent sequence similarity among the homology arms should be analyzed separately for the 5’ and 3’ arms. Figure 1A, or any of the other gene diagrams are not to scale and should indicate this. Next, the authors should report on how many different ESC, iPSC, and MEF clonal lines were used to produce the data presented in Figure 2, as well as what passage number. If a single clonal cell line were used for each, this limits the generalizability of their findings. Furthermore, if these properties change over prolonged passaging of cell lines, this could also explain effects on efficiency. An ideal experiment to truly compare epigenetic states would be to conduct HR experiments on cell types derived from the same genetic individual. For instance, the authors could in vitro differentiate an ESC line into somatic cells such as fibroblasts, then reprogram them into iPSCs, and perform HR experiments on all three epigenetic states. Methodologically, the PCR should be designed in a way to detect a PCR product produced from the wild type alleles, as opposed to seeing no PCR product amplified. When no PCR band is detected for that sample, it could have resulted from a failed PCR run. The agarose gel images should be presented. Additionally, the authors should indicate where and whether the qPCR primers and antibody epitope account for exon 2. Lastly, what is the contribution of cell cycle of each cell type to the HR efficiency? Could a difference in cell cycling rate between the ESC and iPSC lines examined explain the difference in the rate of successful targeting? In sum, this manuscript falls short of the technical standards and logical conclusions expected from PLOS publications. Until the authors address the shortcomings described above and write a coherent story based on tenable data, this work should not be published as presented. Reviewer #2: Tan and co-workers explore the efficiency of traditional gene targeting of the murine Myh9 locus. The work in the manuscript is focused on the mouse Myh9 locus, however, the discussion includes speculation about other species with relatively shallow bioinformatics analysis. Conversely, detailed analysis of the murine Myh9 locus and the sequence of the homology arms lacks any sizable detail. While the identification of the murine Myh9 locus as a mitotic recombination hotspot would be of interest for the field of genome editing, especially for those trying to optimize gene targeting, the manuscript as-is lacks any in depth analysis. The manuscript is both highly speculative about the underlying cause of the high efficiency targeting, while being relatively shallow about the details of the actual molecular work that was done. The manuscript would be greatly improved if it was focused on the mouse Myh9 locus and provided greater details about the various targeting vectors utilized and the genome editing efficiencies observed. Major Comments 1) The comparison of the Myh9 locus in various species does not provide any insight into the high targeting efficiency of the murine Myh9 locus. In this manuscript, only the mouse genome is targeted, and it is inappropriate to infer anything about the targeting potential of the Myh9 locus in these other species, and the contribution of the flanking genomic sequence and the species-specific Myh9 locus. Unless IPSCs from these various species are also used for homologous gene targeting of the Myh9 locus, there is little information to be gained from comparing the Myh9 loci. 2) Although many aspects of homologous directed targeting remain unknown, it is accepted that critical for homologous targeting is mitosis and proliferation. Therefore, the inability to target the Myh9 locus in MEFs, which have a lower proliferative index and readily senescence in culture, is not surprising. The lack of senescence and high proliferation rate of ESCs and IPSCs is critical for efficient homologous gene targeting. Therefore, the expression level of Myh9 in MEFs is inconsequential in this reviewer’s opinion. The proliferation rate/index of the IPSCs and ESCs used in this study should be compared. 3) With gene targeting efficiency over 50%, it would be expected that some of the clones to be homozygous for the targeted allele. For a locus specific report about homologous targeting, zygosity of targeting should be added to the manuscript. 4) The data presented in Table 4 has a good linear relationship between total homology length and targeting efficiency. As presented in the table, it is difficult to see that relationship. 5) The varying targeting efficiency between the three regions of the murine Myh9 locus discussed in Table 3 warrant some additional sequence analysis, such as GC content, repetitive elements, homology to other location in the murine genome, etc. 6) Was chromatin accessibility assessed for the Myh9 locus? Even if not in the actual ESC line used, it would be interesting to know the status of the chromatin/nucleosome in mESCs of the readily targetable Myh9 locus. Minor Comments 1) Minor grammatical errors such as line 64: “…is rarely” 2) Line 142/143; the purpose of the sub-cloning is unclear. 3) The choice of using the 129-derived BAC DNA as a template for the homology arms and the use of B6129F1 ES cells for electroporation is unclear given that isogenic homology arms are believed to increase targeting efficiency (Line 68). 4) If available, the targeting efficiency of the Myh9 locus in the absence of negative selection (ganciclovir) would be a useful comparison, since negative selection in practice rarely results in the enrichment of correctly targeted clones that are conceptually expected. 5) Source/method of IPSCs generation not indicated. Reviewer #3: In this study, the authors intend to investigate the molecular biology underlying for the pronounced high gene targeting frequency at Myh9 gene locus. Numerous factors which affect the HR efficiency were investigated, including chromosome position, transcriptional activity, targeted loci, and the length of the homology arm. And details see the attachment. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.
|
Revision 1 |
PONE-D-19-15918R1 Investigation of the molecular biology underlying the pronounced high gene targeting frequency at the Myh9 gene locus in mouse embryonic stem cells PLOS ONE Dear Dr Wang, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. We would appreciate receiving your revised manuscript by January 10, 2020. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Wenhui Hu, M.D., Ph.D. Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: (No Response) Reviewer #2: All comments have been addressed Reviewer #3: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Yes Reviewer #3: Partly ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: (No Response) ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Tan et al. have removed and analyzed existing data to address reviewers’ concerns about the original draft of their manuscript. Their existing findings and conclusions relating gene targeting (GT) efficiency to cell type (i.e. ESC, iPSC, and MEF) have been removed to focus on the mechanisms underlying GT at the mouse Myh9 locus in ESCs. In response to reviewers’ suggestions, the authors have also analyzed genome sequence elements such as CG content, SSR, and SINE to consider functional elements possibly contributing to the high GT efficiency, specifically at the immediate regions flanking exon 2, which serve as the homology arms. They present this analysis on other species for comparison as well as present sequence elements for their other targeting sequences at intron 2 and exon 3. They have also presented gel images in the figures to show the outcome of their PCR results. Finally, the authors performed correlation analysis between total length of homology arms and targeting efficiency to quantitatively demonstrate a relationship. The major concern remaining with the currently revised manuscript is the relevance of the genomics sequence comparison with other species. All three reviewers raised this concern and recognized that without GT efficiency data from other species, the comparison of genomic features is meaningless. The cross-species comparison of the locus sequence similarity is not an effective method to convey the mechanism of the high GT efficiency. One cannot draw any association between genetic features to function when data on function is completely not presented. This effort is better applied to compare genomics features among the Myh9 locus with other mouse loci that have regularly been used for GT in mouse ESCs, such as Rosa26, HPRT, or Col1a1, where the GT efficiency has been reported by other groups (PMID: 25143803, PMID: 17183668, PMID: 16400644, PMID: 19141541). While it would be more scientifically rigorous to for the authors to perform these GT experiments at these other loci themselves in the same cell lines they have reported on in this manuscript, they can perform meta-analysis by drawing associations based on data previously published by other labs based on their targeting constructs. Despite this reviewer’s opinion that the species comparisons should not be performed and that the data do not support the authors’ conclusion, there are critical misinterpretations of the data as they are currently presented: The methods section describes analyzing only the flanking 5’ and 3’ sequences of Myh9 exon 2 in all species. This is not presented in Figure 1A, which makes it rather misleading to think that Figures 1B, C, and D are based on Figure 1A. In Figure 1A, why is the orientation of the Myh9 loci reversed for the Pig and the Rabbit? This is confusing when the authors refer the right and left arm, rather than the 5’ and 3’ sequences. In Figure 1B, C, and D, the relationships are simply reflecting what is expected to be the relationship on a genome wide level, therefore one should not be surprised that mouse and rat bear such a high degree of similarity. Also, the algorithm for calculating percent identity and divergence should be clearly described for the reader. Figure 2: PCR data is missing for intron 2. Figure 3 is mislabeld as Figure 4. The targeting construct series can benefit the reader by listing properties of each construct to the left of each diagram, such as combined length of homology arms, the ratio of 5’:3’, etc. the length of each arm should also be displayed next to each line. Figure 3C is basically Figure 3D, but it is not appropriate to apply this type of graphing to this data set. The authors should only present scatter plots in the style of Figure 3D. In Figure 3D, the authors perform a quantitative measure of the relationship between total length of homology arms and GT efficiency. They can test the significance of this correlation. The authors should also perform similar quantifiable analysis using the ratio of 5’:3’ lengths, GC content, SSR, and SINE of total, and individual homology arms. These analyses may provide some more insight into the mechanisms underlying the respective GT efficiencies. Table 4. Why is only one repeat shown? Or is this the sum of 2 repeats? Authors should specify. Altogether, the manuscript as presented lack sufficient data to model a hypothesis, much less support a detailed, mechanistic understanding of why the Myh9 locus at exon 2 is such an efficient site for GT. The suggested, more in-depth analyses could bring this manuscript to a body of work suitable for publication in PLOS One. Reviewer #2: The manuscript is greatly improved, and is much more focused on the underlying data and findings. The level of detail provided will allow others to potentially use the murine Myh9 locus as a site to further optimize gene targeting. My only remaining concern (which was shared by other initial reviewers) is the comparison of the murine Myh9 locus with that of other species. With zero gene targeting information for the Myh9 locus in these other species, this is just a distraction for the reader. The inbred mouse is an invaluable tool in biomedical research, and this manuscript should focus on the murine Myh9 locus without speculating about orthologous sequence and how that relates or does NOT relate to the gene targeting. Furthermore, it is misleading to assume that "No unique features and low sequence similarity are found in the Myh9 gene" when comparing to other Myh9 loci for which there is zero gene targeting information. Perhaps a better comparison would be to randomly sample other murine paralogs or similar length/structure loci to see if there is something unique to the murine Myh9 locus that affords such high gene targeting efficiency. Reviewer #3: Tan et al have partially addressed some concerns issued on their manuscript, "Investigation of the molecular biology underlying the pronounced high gene targeting frequency at the Myh9 gene locus in mouse embryonic stem cells." The reasons for similar length of the homologous arms have been properly elucidated. And the further bioinformatic analysis have been performed. However, some issues still should be addressed or discussed to make the manuscript fit for publication in plos one. Comment-1 As mentioned before, the authors analyzed the locus of the Myh9 gene in multiple species. While there is no data showing the GT frequency in these species. Therefore, it’s hardly to reach the conclusion that low correlation with the high GT frequency at the Myh9 gene in term of chromosome position from the variable or conserved the locus Myh9 and its flanking genes. Comment-2 The authors used the V6.5 ESCs which were derived from F1 hybrid mice, with 50% 129S6/SvEv and 50% C57BL/6 for gene targeting, and declared the constructs are isogenic to one of the two chromosomes, while there is no data shows the homology between 129S6/SvEv and C57BL/6 in this loci. Is there evidence that HR is occurs only in the Myh9 loci of 129S6/SvEv? If not, maybe there were some homozygous clones for the targeted allele, which may result in bias for colony picking, as the authors mention, for homozygous knockout of Myh9 can cause abnormal proliferation and ESC morphology. If homology is low, is the targeting efficiency of the Myh9 loci in C57BL/6 as high as 129S6/SvEv? Comment-3 Unformal writing of gene name such as line 40 “…Myh9 (Italic), line 170 “…MYH9” and Figure 1A. In Figure 3C, the units of vertical and horizontal axis should be provided. In Figure 3D, as targeting efficiency will not be lower than 0, it is more appropriate to set the minimum value of the vertical axis to 0. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
Revision 2 |
PONE-D-19-15918R2 Investigation of the molecular biology underlying the pronounced high gene targeting frequency at the Myh9 gene locus in mouse embryonic stem cells PLOS ONE Dear Dr Wang, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the minor points raised during the second review process. We would appreciate receiving your revised manuscript by March 1, 2020. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Wenhui Hu, M.D., Ph.D. Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed Reviewer #3: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Partly ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: (No Response) Reviewer #2: The manuscript in its second revised form is greatly improved. The removal of speculative gene targeting of the Myh9 locus in other species from the main manuscript places focus on the actual work done. Supplementary Figure 1 is poor resolution (and completely unnecessary). While I understand that the multi-species Myh9 locus alignment was time consuming to generate, it really does not add anything of value to the manuscript. Figure 2C and 2D are the exact same data. there is no need to present the same data twice, just add a trend line to 2C (scale on 2D is nonsensical, -20% targeting efficiency?) throughout the paper the Myh9 introns and exons are capitalized and written both with and without a space before the number (e.g. Exon2, Exon 2, Intron2, Intron2, etc). Intent is obvious, but it should be at least consistent within the manuscript. Decision to capitalize intron and exon is questionable, but not a scientific issue. Reviewer #3: Tan et al. have removed the comparison of the Myh9 locus from multiple species, and according to reviewers’ suggestion, the authors compared the length of homologous arms and genomics elements (CG content, SSR, CpG islands, Line, SINE) of the Myh9 locus with other mouse loci (Rosa26, HPRT, and Col1a1) that have widely been used for GT to reveal characteristics potentially contributing to the high GT efficiency. They have also analyzed genomics features of the truncated homologous arms. Comment-1 The author removed the comparison of the Myh9 locus from multiple species, however, retains the alignment of these sequences in Supplementary Figure 1, and it may more preferably to removed Supplementary Figure 1 together. Comment-2 Without GT efficiency data from other mouse loci with different ration of homologous arms, it is inappropriate to infer 2:1 ratio for the length of the 5’ and 3’ homologous arms facilitate GT efficiency from the result of comparison the Myh9 locus with other loci. Comment-3 As other reviewer’ suggestion, Figure 3C is basically Figure 3D, the authors should only present Figure 3D and removed Figure 3C. The concern remaining in the Figure 3D, as targeting efficiency will not be lower than 0, it is more appropriate to set the minimum value of the vertical axis to 0. Comment-4 In Figure 2A, No.2 total length is 4.6 kb, and the right homologous arm of No.3 should be left aligned. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
Revision 3 |
Investigation of the molecular biology underlying the pronounced high gene targeting frequency at the Myh9 gene locus in mouse embryonic stem cells PONE-D-19-15918R3 Dear Dr. Wang, We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements. Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication. Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. With kind regards, Wenhui Hu, M.D., Ph.D. Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
Formally Accepted |
PONE-D-19-15918R3 Investigation of the molecular biology underlying the pronounced high gene targeting frequency at the Myh9 gene locus in mouse embryonic stem cells Dear Dr. Wang: I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. For any other questions or concerns, please email plosone@plos.org. Thank you for submitting your work to PLOS ONE. With kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Wenhui Hu Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .